Procalcitonin measurements for guiding antibiotic treatment in pediatric pneumonia

被引:137
作者
Esposito, Susanna [1 ]
Tagliabue, Claudia [1 ]
Picciolli, Irene [1 ]
Semino, Margherita [1 ]
Sabatini, Caterina [1 ]
Consolo, Silvia [1 ]
Bosis, Samantha [1 ]
Pinzani, Raffaella [1 ]
Principi, Nicola [1 ]
机构
[1] Univ Milan, Dept Maternal & Pediat Sci, Fdn IRCCS Ca Granda, Osped Maggiore Policlin, I-20122 Milan, Italy
关键词
Antibiotic therapy; Antibiotics; Children; Community-acquired pneumonia; Pediatrics; Procalcitonin; RESPIRATORY-TRACT INFECTIONS; C-REACTIVE PROTEIN; COMMUNITY-ACQUIRED PNEUMONIA; ERYTHROCYTE SEDIMENTATION-RATE; SERUM PROCALCITONIN; PNEUMOCOCCAL PNEUMONIA; BACTERIAL PNEUMONIA; CHILDREN; INTERLEUKIN-6; MULTICENTER;
D O I
10.1016/j.rmed.2011.09.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In order to evaluate the use of an algorithm based on a procalcitonin (PCT) cut-off value as a means of guiding antibiotic therapy, 319 hospitalised children with uncomplicated community-acquired pneumonia (CAP) were randomised 1:1 to be treated on the basis of the algorithm or in accordance with standard guidelines. The children in the PCT group did not receive antibiotics if their PCT level upon admission was <0.25 ng/mL, and those receiving antibiotics from the time of admission were treated until their PCT level was >0.25 ng/mL. The final analysis was based on 155 patients in the PCT group and 155 in the control group. In comparison with the controls, the PCT group received significantly fewer antibiotic prescriptions (85.8% vs 100%; p < 0.05), were exposed to antibiotics for a shorter time (5.37 vs 10.96 days; p < 0.05), and experienced fewer antibiotic-related adverse events (3.9% vs 25.2%; p < 0.05), regardless of CAP severity. There was no significant between-group difference in recurrence of respiratory symptoms and new antibiotic prescription in the month following enrollment. The results of this first prospective study using a PCT cut-off value to guide antibiotic therapy for pediatric CAP showed that this approach can significantly reduce antibiotic use and antibiotic-related adverse events in children with uncomplicated disease. However, because the study included mainly children with mild to moderate CAP and the risk of the use of the algorithm-based approach was not validated in a relevant number of severe cases, further studies are needed before it can be used in routine clinical practice. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1939 / 1945
页数:7
相关论文
共 50 条
  • [31] Clinical Significance of Serum Procalcitonin in Patients with Community-acquired Lobar Pneumonia
    Lee, Jin Yong
    Hwang, Su Jin
    Shim, Jae Won
    Jung, Hye Lim
    Park, Moon Soo
    Woo, Hee Yeon
    Shim, Jung Yeon
    [J]. KOREAN JOURNAL OF LABORATORY MEDICINE, 2010, 30 (04): : 406 - 413
  • [32] Procalcitonin as a diagnostic marker of ventilator-associated pneumonia in cardiac surgery patients
    Jiao, Jia
    Wang, Min
    Zhang, Jianfeng
    Shen, Kangjun
    Liao, Xiaobo
    Zhou, Xinmin
    [J]. EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2015, 9 (03) : 1051 - 1057
  • [33] Procalcitonin: The marker of pediatric bacterial infection
    Memar, Mohammad Yousef
    Varshochi, Mojtaba
    Shokouhi, Behrooz
    Asgharzadeh, Mohammad
    Kafil, Hossein Samadi
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2017, 96 : 936 - 943
  • [34] Procalcitonin-guided antibiotic discontinuation in ventilator-associated pneumonia: a prospective observational study
    Wang, Qiushi
    Hou, Dapeng
    Wang, Jing
    An, Kai
    Han, Chenghe
    Wang, Chunting
    [J]. INFECTION AND DRUG RESISTANCE, 2019, 12 : 815 - 824
  • [35] Procalcitonin guided antibiotic therapy of acute exacerbations of asthma: a randomized controlled trial
    Tang, Jianguo
    Long, Wei
    Yan, Lei
    Zhang, Yu
    Xie, Juan
    Lu, Gang
    Yang, Chunhui
    [J]. BMC INFECTIOUS DISEASES, 2013, 13
  • [36] A Systematic Review on the Diagnosis of Pediatric Bacterial Pneumonia: When Gold Is Bronze
    Lynch, Tim
    Bialy, Liza
    Kellner, James D.
    Osmond, Martin H.
    Klassen, Terry P.
    Durec, Tamara
    Leicht, Robin
    Johnson, David W.
    [J]. PLOS ONE, 2010, 5 (08):
  • [37] Role of procalcitonin in diagnosis of community acquired pneumonia in Children
    Ratageri, Vinod H.
    Panigatti, Puspha
    Mukherjee, Aparna
    Das, Rashmi R.
    Goyal, Jagdish Prasad
    Bhat, Javeed Iqbal
    Vyas, Bhadresh
    Lodha, Rakesh
    Singhal, Deepak
    Kumar, Prawin
    Singh, Kuldeep
    Mahapatro, Samarendra
    Charoo, Bashir Ahmad
    Kabra, S. K.
    Jat, K. R.
    [J]. BMC PEDIATRICS, 2022, 22 (01)
  • [38] Design and rationale of the Procalcitonin Antibiotic Consensus Trial (ProACT), a multicenter randomized trial of procalcitonin antibiotic guidance in lower respiratory tract infection
    Huang, David T.
    Angus, Derek C.
    Chang, Chung-Chou H.
    Doi, Yohei
    Fine, Michael J.
    Kellum, John A.
    Peck-Palmer, Octavia M.
    Pike, Francis
    Weissfeld, Lisa A.
    Yabes, Jonathan
    Yealy, Donald M.
    [J]. BMC EMERGENCY MEDICINE, 2017, 17
  • [39] Procalcitonin is useful in identifying bacteraemia among children with pneumonia
    Nascimento-Carvalho, Cristiana M.
    Cardoso, Maria-Regina A.
    Barral, Aldina
    Araujo-Neto, Cesar A.
    Guerin, Sylvie
    Saukkoriipi, Annika
    Paldanius, Mika
    Vainionpaa, Raija
    Lebon, Pierre
    Leinonen, Maija
    Ruuskanen, Olli
    Gendrel, Dominique
    [J]. SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2010, 42 (09) : 644 - 649
  • [40] Clinical usefulness of serum procalcitonin to distinguish between viral pneumonia and Mycoplasma pneumonia in children: A multicenter, cross-sectional study
    Kim, Sungmin
    Hur, Gye
    Sung, Myong Soon
    Baek, Hey-Sung
    Yoon, Jung Won
    Choi, Sun Hee
    Sheen, Youn Ho
    Han, Man Yong
    [J]. ALLERGY ASTHMA & RESPIRATORY DISEASE, 2019, 7 (01): : 22 - 27